Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy
Key facts
- Who runs it
- Shusheng Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 2,734 people enrolled
- Started
- 1 Jan 2019
- Ended
- 30 Nov 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- ulinastatin
- Record updated
- 31 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- age ≥18 years
- ICU stay ≥24 hours
- ulfillment of the diagnostic criteria for sepsis according to the Sepsis-3 definition, which included:
- (a) suspected or confirmed infection based on clinical evidence and/or positive microbiological findings
- (b) Sequential Organ Failure Assessment (SOFA) score ≥2 points
Who cannot take part
- cognitive impairment related to sedation
- inability to communicate effectively due to visual, auditory, or language disorders
- primary central nervous system diseases (e.g., cerebrovascular disease, central nervous system infection, autoimmune encephalitis, or epileptic seizures)
- intolerance or allergy to benzodiazepines, or a history of myasthenia gravis, schizophrenia, or severe depressive disorder
- pregnancy
- metabolic encephalopathy (including hypoglycemia, diabetic ketoacidosis, hepatic encephalopathy, pulmonary encephalopathy, or uremic encephalopathy)
- poisoning
- skull fracture or intracranial injury
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was conducted to explore the association between ulinastatin treatment and the incidence of sepsis-associated encephalopathy (SAE) in patients with sepsis. The study was divided into two phases: first, a multicenter retrospective observational cohort: to evaluate the correlation between ulinastatin treatment and the risk of SAE; second, a single center prospective observational cohort: to further explore the association between ulinastatin treatment and SAE.
The 2 groups in the trial
- Ulinastatin Group
Patients diagnosed with sepsis who received ulinastatin as part of routine clinical care. The use of ulinastatin was not assigned by study protocol but determined by treating physicians. Clinical outcomes, including the incidence of SAE, were assessed.
Treatment: ulinastatin
- Non-Ulinastatin Group
Patients diagnosed with sepsis who did not receive ulinastatin treatment during hospitalization. Clinical outcomes, including the incidence of SAE, were recorded. No study-specific interventions were applied.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 31 July 2025